CA2959207A1 - Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine - Google Patents

Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine Download PDF

Info

Publication number
CA2959207A1
CA2959207A1 CA2959207A CA2959207A CA2959207A1 CA 2959207 A1 CA2959207 A1 CA 2959207A1 CA 2959207 A CA2959207 A CA 2959207A CA 2959207 A CA2959207 A CA 2959207A CA 2959207 A1 CA2959207 A1 CA 2959207A1
Authority
CA
Canada
Prior art keywords
cell
cells
cytokine
subject
antigenic molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2959207A
Other languages
English (en)
French (fr)
Other versions
CA2959207C (en
Inventor
Anders Hogset
Pal Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PCI Biotech AS
Original Assignee
PCI Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201415247A external-priority patent/GB201415247D0/en
Priority claimed from GB201420773A external-priority patent/GB201420773D0/en
Application filed by PCI Biotech AS filed Critical PCI Biotech AS
Publication of CA2959207A1 publication Critical patent/CA2959207A1/en
Application granted granted Critical
Publication of CA2959207C publication Critical patent/CA2959207C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2959207A 2014-08-28 2015-08-28 Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine Active CA2959207C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201415247A GB201415247D0 (en) 2014-08-28 2014-08-28 Compound and method
GB1415247.4 2014-08-28
GB201420773A GB201420773D0 (en) 2014-11-21 2014-11-21 Compound and method
GB1420773.2 2014-11-21
PCT/EP2015/069794 WO2016030529A1 (en) 2014-08-28 2015-08-28 Compound and method

Publications (2)

Publication Number Publication Date
CA2959207A1 true CA2959207A1 (en) 2016-03-03
CA2959207C CA2959207C (en) 2024-09-10

Family

ID=

Also Published As

Publication number Publication date
JP7079819B2 (ja) 2022-06-02
AU2015308345B2 (en) 2020-12-10
JP2020182486A (ja) 2020-11-12
CN108136016A (zh) 2018-06-08
EP3185901A1 (en) 2017-07-05
KR102678732B1 (ko) 2024-06-25
EP3185901C0 (en) 2023-10-04
NZ729408A (en) 2021-12-24
KR20170047336A (ko) 2017-05-04
US10537639B2 (en) 2020-01-21
WO2016030529A1 (en) 2016-03-03
AU2015308345B9 (en) 2020-12-24
BR112017003486A2 (pt) 2018-01-16
US20170252441A1 (en) 2017-09-07
JP2017526371A (ja) 2017-09-14
AU2015308345A1 (en) 2017-03-16
EP3185901B1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
EP3038619B1 (en) Compound and method for vaccination and immunisation
US10556929B2 (en) Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
CA2922467A1 (en) Oncology vaccine
EP3265120B1 (en) Method
AU2018229741A1 (en) Peptides and methods for the treatment of diabetes
CA2811957A1 (en) Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
JP2017509642A (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
JP7079819B2 (ja) 化合物および方法
US20160040128A1 (en) Method
CA2945220C (en) Method of treating melanoma
WO2015028575A1 (en) Immunisation method by photochemical internalisation
CA2959207C (en) Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine
WO2016030528A1 (en) Compound and method
CA2557654A1 (en) Peptides of il1 beta and tnf alpha and method of treatment using same
US20220054631A1 (en) MHC Class I Associated Hepatitis B Peptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821

EEER Examination request

Effective date: 20200821